Ph.D., Global Head of Business Development and Customer Solutions, biomodal
biomodal
Liquid biopsy for profiling cell-free DNA holds promise to transform how we manage cancer by early detection and identification of residual disease and subtype. biomodal’s duet multiomics solution +modC generates data from low input amounts, obtains more sensitive somatic variant calling, and obtains multimodal information to discriminate cancer patients from healthy controls.
Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.